Cargando…

The Role of Glucocorticoids in Breast Cancer Therapy

Glucocorticoids (GCs) are anti-inflammatory and immunosuppressive steroid molecules secreted by the adrenal gland and regulated by the hypothalamic–pituitary–adrenal (HPA) axis. GCs present a circadian release pattern under normal conditions; they increase their release under stress conditions. Thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitre-Aguilar, Irma B., Moreno-Mitre, Daniel, Melendez-Zajgla, Jorge, Maldonado, Vilma, Jacobo-Herrera, Nadia J., Ramirez-Gonzalez, Victoria, Mendoza-Almanza, Gretel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858160/
https://www.ncbi.nlm.nih.gov/pubmed/36661673
http://dx.doi.org/10.3390/curroncol30010024
_version_ 1784874029427982336
author Mitre-Aguilar, Irma B.
Moreno-Mitre, Daniel
Melendez-Zajgla, Jorge
Maldonado, Vilma
Jacobo-Herrera, Nadia J.
Ramirez-Gonzalez, Victoria
Mendoza-Almanza, Gretel
author_facet Mitre-Aguilar, Irma B.
Moreno-Mitre, Daniel
Melendez-Zajgla, Jorge
Maldonado, Vilma
Jacobo-Herrera, Nadia J.
Ramirez-Gonzalez, Victoria
Mendoza-Almanza, Gretel
author_sort Mitre-Aguilar, Irma B.
collection PubMed
description Glucocorticoids (GCs) are anti-inflammatory and immunosuppressive steroid molecules secreted by the adrenal gland and regulated by the hypothalamic–pituitary–adrenal (HPA) axis. GCs present a circadian release pattern under normal conditions; they increase their release under stress conditions. Their mechanism of action can be via the receptor-independent or receptor-dependent pathway. The receptor-dependent pathway translocates to the nucleus, where the ligand-receptor complex binds to specific sequences in the DNA to modulate the transcription of specific genes. The glucocorticoid receptor (GR) and its endogenous ligand cortisol (CORT) in humans, and corticosterone in rodents or its exogenous ligand, dexamethasone (DEX), have been extensively studied in breast cancer. Its clinical utility in oncology has mainly focused on using DEX as an antiemetic to prevent chemotherapy-induced nausea and vomiting. In this review, we compile the results reported in the literature in recent years, highlighting current trends and unresolved controversies in this field. Specifically, in breast cancer, GR is considered a marker of poor prognosis, and a therapeutic target for the triple-negative breast cancer (TNBC) subtype, and efforts are being made to develop better GR antagonists with fewer side effects. It is necessary to know the type of breast cancer to differentiate the treatment for estrogen receptor (ER)-positive, ER-negative, and TNBC, to implement therapies that include the use of GCs.
format Online
Article
Text
id pubmed-9858160
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98581602023-01-21 The Role of Glucocorticoids in Breast Cancer Therapy Mitre-Aguilar, Irma B. Moreno-Mitre, Daniel Melendez-Zajgla, Jorge Maldonado, Vilma Jacobo-Herrera, Nadia J. Ramirez-Gonzalez, Victoria Mendoza-Almanza, Gretel Curr Oncol Review Glucocorticoids (GCs) are anti-inflammatory and immunosuppressive steroid molecules secreted by the adrenal gland and regulated by the hypothalamic–pituitary–adrenal (HPA) axis. GCs present a circadian release pattern under normal conditions; they increase their release under stress conditions. Their mechanism of action can be via the receptor-independent or receptor-dependent pathway. The receptor-dependent pathway translocates to the nucleus, where the ligand-receptor complex binds to specific sequences in the DNA to modulate the transcription of specific genes. The glucocorticoid receptor (GR) and its endogenous ligand cortisol (CORT) in humans, and corticosterone in rodents or its exogenous ligand, dexamethasone (DEX), have been extensively studied in breast cancer. Its clinical utility in oncology has mainly focused on using DEX as an antiemetic to prevent chemotherapy-induced nausea and vomiting. In this review, we compile the results reported in the literature in recent years, highlighting current trends and unresolved controversies in this field. Specifically, in breast cancer, GR is considered a marker of poor prognosis, and a therapeutic target for the triple-negative breast cancer (TNBC) subtype, and efforts are being made to develop better GR antagonists with fewer side effects. It is necessary to know the type of breast cancer to differentiate the treatment for estrogen receptor (ER)-positive, ER-negative, and TNBC, to implement therapies that include the use of GCs. MDPI 2022-12-25 /pmc/articles/PMC9858160/ /pubmed/36661673 http://dx.doi.org/10.3390/curroncol30010024 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mitre-Aguilar, Irma B.
Moreno-Mitre, Daniel
Melendez-Zajgla, Jorge
Maldonado, Vilma
Jacobo-Herrera, Nadia J.
Ramirez-Gonzalez, Victoria
Mendoza-Almanza, Gretel
The Role of Glucocorticoids in Breast Cancer Therapy
title The Role of Glucocorticoids in Breast Cancer Therapy
title_full The Role of Glucocorticoids in Breast Cancer Therapy
title_fullStr The Role of Glucocorticoids in Breast Cancer Therapy
title_full_unstemmed The Role of Glucocorticoids in Breast Cancer Therapy
title_short The Role of Glucocorticoids in Breast Cancer Therapy
title_sort role of glucocorticoids in breast cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858160/
https://www.ncbi.nlm.nih.gov/pubmed/36661673
http://dx.doi.org/10.3390/curroncol30010024
work_keys_str_mv AT mitreaguilarirmab theroleofglucocorticoidsinbreastcancertherapy
AT morenomitredaniel theroleofglucocorticoidsinbreastcancertherapy
AT melendezzajglajorge theroleofglucocorticoidsinbreastcancertherapy
AT maldonadovilma theroleofglucocorticoidsinbreastcancertherapy
AT jacoboherreranadiaj theroleofglucocorticoidsinbreastcancertherapy
AT ramirezgonzalezvictoria theroleofglucocorticoidsinbreastcancertherapy
AT mendozaalmanzagretel theroleofglucocorticoidsinbreastcancertherapy
AT mitreaguilarirmab roleofglucocorticoidsinbreastcancertherapy
AT morenomitredaniel roleofglucocorticoidsinbreastcancertherapy
AT melendezzajglajorge roleofglucocorticoidsinbreastcancertherapy
AT maldonadovilma roleofglucocorticoidsinbreastcancertherapy
AT jacoboherreranadiaj roleofglucocorticoidsinbreastcancertherapy
AT ramirezgonzalezvictoria roleofglucocorticoidsinbreastcancertherapy
AT mendozaalmanzagretel roleofglucocorticoidsinbreastcancertherapy